Evidence map›Paper›PMID 41053606›Full record

ArticleBMC cancer2025

Predicting hematologic toxicity in advanced cervical cancer patients using interpretable machine learning models based on radiomics and dosimetrics.

Jun Zhu, Qionghui Zhou, Luqiao Chen, Zhipeng He, Jianfeng Tan, Jinmeng Pang, Qianxi Ni

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun Zhu *Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
Qionghui Zhou *Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
Luqiao ChenDepartment of Oncology, The First Hospital of Changsha/The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Zhipeng HeDepartment of Radiation Oncology, The First People's Hospital of Chenzhou, Chenzhou, Hunan, China.
Jianfeng TanDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
Jinmeng PangDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
Qianxi NiDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China. niqianxi2014@163.com.

Funding

National Key R&D Program of China 2022YFC2404604the Key Research and Development Program of Climbing Scientific Research Plan of Hunan Cancer Hospital YF2021006The Key Research and Development Program of Hunan Province 2025JK2138the Science and Technology Innovation Program of Hunan Province 2023SK4034
6 · The paper itself

Abstract

BACKGROUND AND

objectivesHematologic toxicity (HT) is a common and serious side effect for advanced cervical cancer patients undergoing chemoradiotherapy. Accurately predicting HT can significantly improve patient management and treatment outcomes. This study aims to develop and evaluate interpretable machine learning models that use radiomic and dosimetric features to predict HT in advanced cervical cancer patients. METHODS AND MATERIALS: Retrospectively collected general clinical data, planning CT images, and dose files from 205 patients with advanced cervical cancer who underwent chemoradiotherapy, and classified them according to the severity of HT. Radiomics and dosiomics features were extracted from the same region of interest, and feature selection was performed using a random forest algorithm. Radiomics models, dosiomics models, and hybrid models were then constructed based on extreme gradient boosting trees. Sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC) were calculated to evaluate the classification performance of the models. Finally, SHAP values were used to perform interpretability analysis on the best model to enhance the transparency and practicality of the model.

resultsThe sensitivity, specificity, and AUC values for the radiomics model were 0.42, 0.86, and 0.78, respectively, while those for the dosiomics model were 0.50, 0.90, and 0.74. In contrast, the hybrid model exhibited superior classification performance with sensitivity, specificity, and AUC values of 0.50, 0.83, and 0.83, respectively. Compared to the standalone radiomics and dosiomics models, the hybrid model demonstrated enhanced classification capability. Interpretability analysis based on SHAP values not only provided a ranking of feature importance and the distribution of feature impacts on model outputs but also elucidated the specific decision-making processes influenced by these features and the interactions between them. This enables clinicians to gain a more intuitive understanding of the model's decisions.

conclusionsFor patients with advanced cervical cancer undergoing chemoradiotherapy, the integration of radiomics and dosiomics features can significantly enhance the classification performance of predictive models, thereby holding considerable potential for refining patient treatment strategies. Interpretability analysis based on SHAP values can aid clinicians in more readily understanding the model's decisions, thus promoting the effective implementation of the model in clinical practice.

Indexed as

ChemoradiotherapyHematologic DiseasesMachine LearningUterine Cervical NeoplasmsAdultAgedFemaleHumansMiddle AgedRadiometryRadiomicsRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRetrospective StudiesROC CurveTomography, X-Ray ComputedDosimicsHematological toxicityMachine learningRadiomicsSHAP

Identifiers

PMID41053606
PMCPMC12502497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.